https://pharmadog.xyz/news/628611 pharmadog en 2026-11-02T17:15:16.000Z FDA policy allowing compounding of unapproved peptides raises safety and development concerns https://pharmadog.xyz/news/628651 pharmadog en 2026-11-02T17:07:00.000Z Karyopharm files for Chapter 11 and plans auction with Gamida Cell parent Ayrmid as lead bidder https://pharmadog.xyz/news/628631 pharmadog en 2026-11-02T17:05:28.000Z Midterm voters weigh health-care costs as urgent-care visits billed like ERs https://pharmadog.xyz/news/628443 pharmadog en 2026-11-02T16:52:45.000Z Sun Pharma halts eye-care drug production in India after regulator cited quality failures https://pharmadog.xyz/news/628463 pharmadog en 2026-11-02T16:47:33.000Z Study finds psilocybin does not produce lasting anxiety or depression relief in mice https://pharmadog.xyz/news/628464 pharmadog en 2026-11-02T16:13:46.000Z FDA grants tentative approval for generic HIV prevention shot, boosting access in low-income nations https://pharmadog.xyz/news/628419 pharmadog en 2026-11-02T16:10:20.000Z FDA sets May 1 decision deadline for UniQure’s Huntington’s disease gene therapy after advisory committee meeting https://pharmadog.xyz/news/628251 pharmadog en 2026-11-02T15:28:10.000Z Karyopharm Therapeutics to merge with Ayrmid as it enters bankruptcy https://pharmadog.xyz/news/628275 pharmadog en 2026-11-02T15:16:02.000Z Tiziana's lower-dose foralumab cuts neuroinflammation in SPMS, but higher dose fails https://pharmadog.xyz/news/628252 pharmadog en 2026-11-02T15:11:58.000Z FDA places Bright Minds seizure drug BMB-101 on partial hold over mouse toxicity, shares plunge https://pharmadog.xyz/news/134233 pharmadog en 2026-11-02T15:08:00.000Z CLINUVEL to cut up to 20% of staff and move headquarters to New York https://pharmadog.xyz/news/628277 pharmadog en 2026-11-02T15:03:52.000Z Cell and gene therapy funding climbs to $2.2 billion in Q3 despite safety setbacks in CAR-T trials https://pharmadog.xyz/news/628107 pharmadog en 2026-11-02T14:41:57.000Z U.S. bioscience jobs up 7% from 2021 to 2025: Report https://pharmadog.xyz/news/628147 pharmadog en 2026-11-02T14:34:00.000Z FDA accepts first Keytruda biosimilar application as Merck faces looming patent cliff https://pharmadog.xyz/news/628108 pharmadog en 2026-11-02T14:32:20.000Z FDA sets May 1 decision date for uniQure's Huntington's disease gene therapy after year-long regulatory saga https://pharmadog.xyz/news/628127 pharmadog en 2026-11-02T14:22:08.000Z Four major drugmakers allegedly paid tens of millions to Russian middlemen for lifesaving drugs, limiting patient access https://pharmadog.xyz/news/628148 pharmadog en 2026-11-02T14:00:00.000Z AstraZeneca outlines restructuring as earnings show cost cuts, while Alnylam slides and Regeneron posts record quarter https://pharmadog.xyz/news/628166 pharmadog en 2026-11-02T13:56:06.000Z FDA issues final guidance on potency assurance for cell and gene therapy manufacturers https://pharmadog.xyz/news/627959 pharmadog en 2026-11-02T13:08:42.000Z Woman travels to Albania for experimental mitochondrial replacement therapy amid global fertility industry concerns https://pharmadog.xyz/news/627771 pharmadog en 2026-11-02T12:28:16.000Z FDA accepts review of Biohaven’s ataxia drug, boosting shares as ArriVent’s lung cancer trial miss drags its stock down https://pharmadog.xyz/news/627747 pharmadog en 2026-11-02T12:00:45.000Z CinRx partners with Graviton Bioscience to target ROCK2 in pulmonary arterial hypertension and other cardiovascular diseases https://pharmadog.xyz/news/628226 pharmadog en 2026-11-02T10:17:00.000Z Karyopharm files Chapter 11 and taps Irish biotech Ayrmid as lead bidder for merger https://pharmadog.xyz/news/627307 pharmadog en 2026-11-02T10:00:00.000Z Pharma leaders turn to integrated scenario modeling as US MFN pricing reshapes global launch strategies https://pharmadog.xyz/news/628395 pharmadog en 2026-11-02T09:55:00.000Z Biossil Labs acquires Theriva's antibiotic-degrader portfolio in up to $91 million deal https://pharmadog.xyz/news/627287 pharmadog en 2026-11-02T09:30:00.000Z STAT calls for input on mitochondrial replacement therapy used in fertility tourism https://pharmadog.xyz/news/627288 pharmadog en 2026-11-02T09:30:00.000Z Kymera Therapeutics to unveil mid‑stage eczema trial data, aiming to challenge Dupixent https://pharmadog.xyz/news/627289 pharmadog en 2026-11-02T09:30:00.000Z Cancer can be treated safely during pregnancy, says maternal-fetal specialist https://pharmadog.xyz/news/627290 pharmadog en 2026-11-02T09:30:00.000Z U.S. Health Care System's Economics Are Broken, Says Ascendiun CEO https://pharmadog.xyz/news/627291 pharmadog en 2026-11-02T09:30:00.000Z Women travel abroad for unproven three-parent IVF marketed to older patients https://pharmadog.xyz/news/628058 pharmadog en 2026-11-02T09:24:00.000Z Teva halts phase 2 trial of emrusolmin for multiple system atrophy after futility analysis https://pharmadog.xyz/news/627890 pharmadog en 2026-11-02T08:43:00.000Z FDA places partial hold on Bright Minds' seizure trial over mouse toxicity concerns https://pharmadog.xyz/news/628060 pharmadog en 2026-11-02T08:40:00.000Z Tiziana's intranasal MS drug shows lower dose cuts neuroinflammation, higher dose falls short in Phase 2a trial https://pharmadog.xyz/news/626823 pharmadog en 2026-11-02T07:04:00.000Z Top pharma firms line up for Summit Therapeutics' ivonescimab after strong China Phase 3 data https://pharmadog.xyz/news/626824 pharmadog en 2026-11-02T07:00:00.000Z FDA issues draft guidance to streamline approval of personalized gene therapies https://pharmadog.xyz/news/626655 pharmadog en 2026-11-02T06:01:00.000Z Saudi Arabia pushes ahead with biotech hub despite regional instability https://pharmadog.xyz/news/627554 pharmadog en 2026-11-02T05:47:00.000Z InventisBio's Phase 3 Trial Shows Nomelcitinib Achieves Over 70% PASI-90 Response in Chinese Psoriasis Patients https://pharmadog.xyz/news/626487 pharmadog en 2026-11-02T05:09:00.000Z BridgeBio eyes first FDA approval for limb-girdle muscular dystrophy therapy